Unknown

Dataset Information

0

First-in-human study assessing safety, tolerability, and pharmacokinetics of 2-hydroxybenzylamine acetate, a selective dicarbonyl electrophile scavenger, in healthy volunteers.


ABSTRACT: BACKGROUND:2-Hydroxybenzylamine (2-HOBA) is a selective scavenger of dicarbonyl electrophiles that protects proteins and lipids from being modified by these electrophiles. It is currently being developed for use as a nutritional supplement to help maintain good health and protect against the development of conditions associated with dicarbonyl electrophile formation, such as the cognitive decline associated with Mild Cognitive Impairment and Alzheimer's disease. METHODS:In this first-in-human study, the safety, tolerability, and pharmacokinetics of six ascending single oral doses of 2-HOBA acetate were tested in eighteen healthy human volunteers. RESULTS:Reported adverse events were mild and considered unlikely to be related to 2-HOBA. There were no clinically significant changes in vital signs, ECG recordings, or clinical laboratory parameters. 2-HOBA was fairly rapidly absorbed, with a tmax of 1-2?h, and eliminated, with a t1/2 of approximately 2?h. Both tmax and t1/2 were independent of dose level, while Cmax and AUC increased proportionally with dose level. CONCLUSIONS:2-HOBA acetate was safe and well-tolerated at doses up to 825?mg in healthy human volunteers, positioning it as a good candidate for continued development as a nutritional supplement. TRIAL REGISTRATION:This study is registered at ClinicalTrials.gov (NCT03176940).

SUBMITTER: Pitchford LM 

PROVIDER: S-EPMC6321651 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

First-in-human study assessing safety, tolerability, and pharmacokinetics of 2-hydroxybenzylamine acetate, a selective dicarbonyl electrophile scavenger, in healthy volunteers.

Pitchford Lisa M LM   Rathmacher John A JA   Fuller John C JC   Daniels J Scott JS   Morrison Ryan D RD   Akers Wendall S WS   Abumrad Naji N NN   Amarnath Venkataraman V   Currey Patricia M PM   Roberts L Jackson LJ   Oates John A JA   Boutaud Olivier O  

BMC pharmacology & toxicology 20190105 1


<h4>Background</h4>2-Hydroxybenzylamine (2-HOBA) is a selective scavenger of dicarbonyl electrophiles that protects proteins and lipids from being modified by these electrophiles. It is currently being developed for use as a nutritional supplement to help maintain good health and protect against the development of conditions associated with dicarbonyl electrophile formation, such as the cognitive decline associated with Mild Cognitive Impairment and Alzheimer's disease.<h4>Methods</h4>In this fi  ...[more]

Similar Datasets

| S-EPMC6945443 | biostudies-literature
| S-EPMC4187916 | biostudies-literature
| S-EPMC7818513 | biostudies-literature
| S-EPMC5890854 | biostudies-literature
| S-EPMC2426925 | biostudies-other
| S-EPMC4040367 | biostudies-literature
| S-EPMC8742633 | biostudies-literature
| S-EPMC3994918 | biostudies-literature
| S-EPMC8301589 | biostudies-literature
| S-EPMC8301559 | biostudies-literature